Anzeige
zum Thema: remimazolamProducts empowering scientists at every stage, helping to deliver scientific breakthroughs. Leading life science supplier for your research, development, or production needs.
Suchergebnisse
31. Juli 2023 · Remimazolam is a short acting benzodiazepine whose effects are terminated by ester hydrolysis Fig. 1.This review briefly summarises remimazolam’s profile in procedural sedation whilst addressing in more detail future opportunities in induction and maintenance of general anaesthesia.
Remimazolam has been successfully used for the induction and maintenance of procedural sedation and general anaesthesia owing to its fast onset, short and predictable duration of sedative action, short recovery time, rare accumulation after long-term infusion, and less serious side effects as compared with those of other currently used BDZs. 16,17 These characteristics render remimazolam a ...
1. Feb. 2023 · Remimazolam may harm an unborn baby, and generally should not be used during pregnancy. Tell your doctor if you are pregnant. If you use remimazolam during pregnancy, your baby could be born with life-threatening sedation or withdrawal symptoms, and may need medical treatment for several weeks.
A novel ultra-short-acting benzodiazepine (BDZ), remimazolam (CNS 7056), has been designed by 'soft drug' development to achieve a better sedative profile than that of the current drugs. Notably, the esterase linkage in remimazolam permits rapid hydrolysis to inactivate metabolites by non-specific t …
The mean time to loss of consciousness and time to extubation were significantly longer for patients treated with remimazolam than in patients treated with propofol (102.0 s for 6 mg/kg/h remimazolam and 88.7 s for 12 mg/kg/h remimazolam vs. 78.7 s for propofol, and 19.2 and 19.2 min vs. 13.1 min, respectively) .
22. Juni 2023 · Remimazolam is an ultra-short acting benzodiazepine used intravenously for induction and maintenance of sedation for adults undergoing short term procedures not requiring general anesthesia. Remimazolam sedation has not been associated with serum aminotransferase elevations and has not been linked to cases of clinically apparent liver injury.
Remimazolam ist ein Benzodiazepin und besitzt innerhalb dieser Gruppe eine einmalige Kinetik: es wird organunabhängig innerhalb von Minuten in einen nichtaktiven Metaboliten verstoffwechselt. Die ultrakurze Wirkdauer erklärt sich durch den Abbau über ubiquitär vorkommende unspezifische Gewebsesterasen.
Anzeige
zum Thema: remimazolamProducts empowering scientists at every stage, helping to deliver scientific breakthroughs. Leading life science supplier for your research, development, or production needs.
